Daniel Muehl - Clovis Oncology Executive
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Executive
Mr. Daniel W. Muehl is Executive Vice President of Finance, Principal Accounting Officer and Principal Financial Officer of the Company since 2019.
| Age | 59 |
| Tenure | 5 years |
| Phone | 303 625 5000 |
| Web | https://www.clovisoncology.com |
Clovis Oncology Management Efficiency
The company has return on total asset (ROA) of (0.3018) % which means that it has lost $0.3018 on every $100 spent on assets. This is way below average. Clovis Oncology's management efficiency ratios could be used to measure how well Clovis Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Clovis Oncology currently holds 436.77 M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology has a current ratio of 1.15, suggesting that it is in a questionable position to pay out its financial obligations when due. Note, when we think about Clovis Oncology's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jonathan Griffin | Balchem | 48 | |
| Job Gunsteren | Balchem | 48 | |
| Danyal Ali | Xponential Fitness | N/A | |
| Valerie Roberts | Jacobs Solutions | N/A | |
| Scot Kathmann | Primoris Services | N/A | |
| Robert Duff | Jacobs Solutions | 65 | |
| Mark Stach | Balchem | 62 | |
| Blake Holcomb | Primoris Services | N/A | |
| Shelette Gustafson | Jacobs Solutions | 59 | |
| Ayan Banerjee | Jacobs Solutions | N/A | |
| Clay Smith | Arq Inc | N/A | |
| Frederic Boned | Balchem | 46 | |
| Garrett Chandler | Arq Inc | N/A | |
| Chad Haxton | Primoris Services | N/A | |
| Venkatesh Nathamuni | Jacobs Solutions | N/A | |
| Jonathan CFA | Jacobs Solutions | N/A | |
| Joseph Wong | Arq Inc | 63 | |
| Thomas McDuffie | Jacobs Solutions | 75 | |
| David Sweet | Griffon | N/A | |
| Rhonda Anderson | Primoris Services | N/A | |
| Martin Reid | Balchem | 56 | |
Management Performance
| Return On Asset | -0.3 |
Clovis Oncology Leadership Team
Elected by the shareholders, the Clovis Oncology's board of directors comprises two types of representatives: Clovis Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clovis. The board's role is to monitor Clovis Oncology's management team and ensure that shareholders' interests are well served. Clovis Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clovis Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna Sussman, VP Relations | ||
| Patrick MA, CEO, CoFounder | ||
| BSc BSc, Exec Officer | ||
| Paul Gross, Executive Vice President Chief Compliance Officer, General Counsel | ||
| Ann Bozeman, Executive Vice President of Human Resources | ||
| Thomas BSc, Ex Officer | ||
| Daniel Muehl, Principal Financial Officer, Principal Accounting Officer |
Clovis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clovis Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |